Recently, we showed that baculovirus (BV)-infected dendritic cells (DCs) (BV-DCs) induced antitumor immunity against established tumors in mice. These antitumor effects were CD8 + T-cell and natural killer (NK) cell dependent but CD4 + T-cell independent. In the current study, we examined the antitumor effect of BV-DCs on human pancreatic cancer cells (AsPC-1). After treatment with BV-infected bone marrow-derived dendritic cells (BMDCs), human pancreatic tumors caused by AsPC-1 cells in a nude mouse model were significantly reduced in size, and the survival of the mice was improved compared with that of non-immature BMDC (iDC)-and BV-DC-immunized mice. We also found that wild-type BV could activate human DCs (HDCs) and that NK cells were activated by BV-infected HDCs (BHDCs). Our findings show that BV-DCs can induce antitumor immunity, which paves the way for the use of this technique as an effective tool for DC immunotherapy against malignancies.
INTRODUCTION
Baculoviruses (BVs) infect a range of mammalian cell types but cannot replicate in them, 1 and they can express foreign genes under mammalian-specific promoters. 2, 3 BVs have a wide range of biotechnological applications as biological control agents and as expression vectors and potential gene delivery agents for in vivo and ex vivo applications, such as regenerative medicine and stem cell transduction. The Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) has also been shown to stimulate the mammalian immune response by acting as an adjuvant. 4 This property is mediated by the innate and adaptive immune responses, including activation of macrophages and the classical complement pathway to promote humoral and CTL responses. [5] [6] [7] The stimulation of innate immune cells increases the production of tumor necrosis factor alpha (TNF-α) 8 and type I interferon (IFN, including IFN-α/β), 9 both of which contribute to the local inflammatory response and impaired antiviral defense. A considerable number of attempts have been made to understand the nature of host immune responses to BV. In vivo studies have found that the virus induces antiviral cytokine production, which protects cells from infection with encephalomyocarditis virus (EMCV) 6 and influenza virus. 10 Abe and coworkers have demonstrated that the production of these proinflammatory cytokines and type I IFN is induced via Toll-like receptor 9 (TLR9)-dependent and TLR9-independent pathways in dendritic cells (DCs) and macrophages. [11] [12] [13] Recently, we have reported that wild-type AcMNPV infects DCs and induces natural killer (NK) celldependent, antimetastatic effects in mice.
14 Additionally, AcMNPV has been shown to suppress liver injury and fibrosis through the stimulation of a beneficial arm of the innate immune system in a mouse liver cirrhosis model. 15 More recently, we showed that BVinfected bone marrow-derived dendritic cells (BMDCs) (BV-DCs) induced antitumor immunity against established tumors in mice.
These antitumor effects were CD8 + T-cell and NK cell dependent but CD4 + T cell independent. 16 Pancreatic cancer is a lethal disease and remains one of the cancers most resistant to traditional therapies. The 5-year survival rate is o5%, 17 and surgery is the only treatment offering longterm survival, but only for a limited number of patients (10 to 20%). Historically, chemotherapy and radiotherapy have not provided a meaningful survival benefit for advanced pancreatic cancer. 18 Recently, some therapies against pancreatic cancer have been developed. Conroy et al. have discussed the efficacy and safety of chemotherapy with gemcitabine and leucovorin (FOLFIRINOX) in patients with metastatic pancreatic cancer. FOLFIRINOX treatment resulted in an improved survival rate compared with gemcitabine, but it had increased toxicity. 19 On the other hand, Von Hoff et al. have shown that nab-paclitaxel plus gemcitabine treatment significantly improves overall survival and response rates but is associated with myelosuppression and peripheral neuropathy. 20 Furthermore, Salmons et al have demonstrated that encapsulated cells that activate a prodrug can also be successfully applied in combination with other, nonprodrug-activating therapies, significantly reducing the side effects of conventional chemotherapy and making the chemotherapy more tolerable. 21 On the other hand, immunotherapies act differently to chemotherapy and radiotherapy and might be an alternative treatment modality with significantly lower toxicity for this deadly disease. 22 Therefore, immunotherapy that is designed to target pancreatic cancer-associated antigens may be a promising treatment approach. Recently, a major area of investigation in cancer immunotherapy has involved the design of DC-based cancer vaccines [23] [24] [25] [26] [27] [28] for pancreatic cancer. 24, [29] [30] [31] [32] [33] In this study, we investigated the induction of antitumor immunity against human pancreatic carcinoma by BV-DCs. We also report that BV-infected human CD1c + myeloid DCs (mDCs) induce NK cell activation. 1 
RESULTS AND DISCUSSION
We previously reported that BV-DCs showed upregulation of costimulatory molecules, such as CD80, CD86 and MHC classes I and II, and increased secretion of IFNs and other proinflammatory cytokines. 4 Moreover, NK cells or T cells co-cultured with BV-DCs produced IFN-γ and exhibited increased cytotoxicity and proliferation. Here, we evaluated whether BV-DCs would induce antitumor immunity against human pancreatic carcinoma cells in a xenograft model using immunodeficient mice. The experimental schedule is shown in Figure 1a . For the in vivo depletion of NK cell activity, nude mice (6-week-old female BALB/c nu/nu) (Nippon SLC, Inc. Shizuoka, Japan) were intraperitoneally (i.p.) injected with anti-asialo GM1 antibody (Ab) (50 μg/mouse; Wako, Osaka, Japan) 1 day before and 3 days after inoculation with tumor cells. To analyze the mice that received the anti-asialo GM1 Ab, spleen cells were stained with the anti-asialo GM1 Ab or normal rabbit sera as a control on days 7 and 14. The stained cells were analyzed with a FACScan (Becton Dickinson, Mountain View, CA) and CellQuest software (Becton Dickinson). Flow cytometry analysis confirmed 495% depletion of the target cells. Murine BMDCs were generated using the same method as described previously. 4 Wild-type BV was purchased from BD Biosciences (San Diego, CA) and propagated in Spodoptera frugiperda (Sf-9) cells in Sf-900 II medium. The BV was purified as previously described, 16 and the viral titer was determined using a plaque assay. CpG-DCs and BVDCs were prepared as described previously. 4 Human pancreatic cancer cells (AsPC-1) (kindly provided by Dr M. Tagawa) were subcutaneously injected into nude mice (3 × 10 6 cells/mouse) on day 0, followed by three intratumoral injections (1 × 10 6 cells/ mouse) of immature BMDCs (iDCs), CpG-DCs or BV-DCs on days 18, 25 and 32. The tumor volumes of the BMDC-treated mice were calculated over time. As shown in Figure 1b , BV-DCs inhibited tumor growth compared with the control BMDCs. The survival time of the mice immunized with BV-DCs was significantly prolonged compared with that of mice inoculated with control BMDCs (Figure 1c) .
Next, we investigated the activation and maturation of mouseand human-derived DCs. Human DCs (HDCs) were harvested from human monocytes (KAC Co., Ltd. Kyoto, Japan) using anti-human CD1c + MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured with GM-CSF and IL-4. The HDCs were infected with BV at an MOI of 10 or stimulated with LPS (1 μg/ml), which served as a positive control. After 24 h of culture, the expression of costimulatory molecules, such as CD80, CD86, the DC activation marker CD83 and MHC classes I and II, on DCs was analyzed by FACS. Additionally, IFN-α, IFN-γ, proinflammatory cytokines, TNF-α, IL-12 and IL-18 levels were analyzed in the culture supernatant by ELISA. The BV-infected HDCs (BHDCs) showed upregulation of costimulatory molecules, such as CD80, CD83, CD86 and MHC classes I and II compared with control HDCs (Figure 2a) , and HDC surface markers were strongly activated by BV infection. The BHDCs secreted IFN-α, IFN-γ, TNF-α, IL-12 and IL-18 at greater levels than the control HDCs (Figure 2b) . Furthermore, the HDCs dose-dependently produced IL-18 upon BV infection at MOI values ranging from 1 to 50 (Figure 2c ). These results suggested that BV induced the upregulation of activation markers on HDCs and the production of proinflammatory cytokines and IFN-α. We also investigated the activation of NK cells by BV-HDCs. Human NK cells were purified from PBMCs (KAC Co., Ltd. Kyoto, Japan) using a Human NK Cell Isolation Kit (Miltenyi Biotec Inc., NordrheinWestfalen, Germany) and co-cultured with BHDCs or LPSstimulated HDCs. After culturing for 18 h, the expression of the activation marker CD69 on human NK cells was analyzed by FACS, and IFN-γ secretion was analyzed by ELISA of the culture supernatant. As shown Figure 3a , the activation marker CD69 was upregulated on human NK cells when co-cultured with BVHDCs compared with co-culture with iHDCs; similar results were observed for human NK cells co-cultured with LPS-stimulated DCs. We also examined IFN-γ production by human NK cells. Human NK cells co-cultured with BV-HDCs as well as human NK cells cocultured with LPS-stimulated HDCs produced IFN-γ (Figure 3b) . Next, human NK cells were co-cultured with BHDCs and used as effector cells, and AsPC-1 cells were used as target cells. BHDCs were added to a human NK cell culture at a DC/NK ratio of 1:2 for 18 h. The cells were then co-cultured at an E:T ratio of 1:1 for 4 h, and cytotoxicity was examined using a CytoTox 96 NonRadioactive Cytotoxicity Assay (Promega, Madison, WI) according to the manufacturer's protocol. AsPC-1 cell-specific cytotoxicity due to BHDC-NK cell co-culture was significantly increased compared with the cytotoxicity caused by human NK cells alone or HDC-human NK cell co-culture (Figure 3c ). These results suggest that wild-type BV is able to activate human monocyte-derived DCs and trigger the activation of NK cells via BHDCs.
In conclusion, we showed that BV-DCs inhibited tumor growth compared with control BMDCs. The survival time of the mice immunized with BV-DCs was also significantly prolonged compared with that of mice inoculated with control BMDCs. Furthermore, we found that BV induces the functional maturation of human monocyte-derived DCs and the activation of human NK cells via BHDCs. BV-DCs might therefore be a useful tool for immunotherapy for viral infections and malignancies, particularly if used in association with current therapies to achieve the most effective results.
MATERIALS AND METHODS
Mice, cell lines and reagents Female nude mice (BALB/c nu/nu, 6 weeks old) were purchased from Nippon SLC (Hamamatsu, Japan). Mice were maintained under specific-pathogen-free-conditions, and all study protocols were approved by the Animal Welfare Committee of Chiba Institute of Technology. Sf-9 cells were cultured at 27°C in BD BaculoGold medium (Invitrogen, Carlsbad, CA, USA), and AsPC-1 cells (provided by Dr Tagawa) were maintained in RPMI-1640 (Sigma Chemical Co., St Louis, MO, USA) supplemented with 10% FBS (Sigma Chemical Co.), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma Chemical Co.). LPS was bought from Sigma Chemical Co. Synthesized CpG-A (ODN-D19) was purchased from Hokkaido System Science (Sapporo, Hokkaido, Japan). Murine and human GM-CSF and murine and human IL-4 were bought from PeproTech EC Ltd. (London, UK). FITC-conjugated anti-human CD69 and CD1a and PE-conjugated anti-human CD80, CD83, CD86, MHC I, MHC II and CD56 were purchased from BioLegend, Inc. (CA, USA) and BD Biosciences (San Diego, CA, USA).
Purification of wild-type BV Wild-type BV was purchased from BD Biosciences, multiplied on a large scale using Sf-9 insect cells and purified as follows. Culture supernatants were harvested 3 to 4 days after infection, and cell debris was removed by centrifugation at 3000 r.p.m. for 5 min. The virus was pelleted by ultracentrifugation at 25000 r.p.m. for 60 min at 4°C and then resuspended in 1 ml of sterile physiological saline (PSS). The infectious titer was determined by a plaque assay.
Generation of murine BMDCs and PBMC-derived HDCs Murine BMDCs (from female nude mice) were generated as described previously. 16 HDCs were generated from PBMCs (purchased from KAC Co., Ltd., Kyoto, Japan). Briefly, PBMCs (1.0 × 10 7 -2.0 × 10 7 ) were cultured in 10 ml RPMI-1640 medium containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 μM L-glutamine (Invitrogen) and 50 μM 2-mercaptoethanol (Invitrogen) and supplemented with 60 ng/ml human GM-CSF and 60 ng/ml human IL-4 in a 100-mm dish. On day 3, the culture medium was replaced with fresh medium supplemented with human GM-CSF and human IL-4 at the same concentrations. On Antitumor effects of BV-infected DCs against pancreatic carcinomawith each type of BMDC when the tumor diameter reached 7-9 mm. The tumor volume was measured every 3 days. For the in vivo depletion of NK cell activity, nude mice were intraperitoneally (i.p.) injected with anti-asialo GM1 Ab (50 μg/mouse; Wako, Osaka, Japan) 1 day before and 3 days after inoculation with the tumor cells. Flow cytometry analysis confirmed 495% depletion of the target cells.
Flow cytometry analysis HDCs (1 × 10 6 /well) were incubated with BV at an MOI of 10 or with LPS (1 μg/ml) for 24 h. PE-conjugated anti-MHC I, anti-MHC II, anti-CD80, anti-CD83 and anti-CD86 and FITC-conjugated antiCD1a (BioLegend, Inc. and BD Biosciences) mAbs were used as primary Abs. The cells were washed and incubated with primary Abs for 1 h at 4°C. Thereafter, the cells were washed and analyzed using a FACSCalibur with CellQuest software (BD Biosciences). HDCs were uninfected, infected with wild-type BV at an MOI of 10 or stimulated with LPS (1 μg/ml). Human NK cells purified from PBMCs were then added and cultured for 18 h, and CD69 expression on human NK cells was analyzed by FACS. (b) Examination of IFN-γ production by human NK cells. HDCs were uninfected, infected with BV at an MOI of 10 or stimulated with LPS (1 μg/ml). Human NK cells purified from PBMCs were then added and cultured for 18 h, and IFN-γ secretion was examined in DC/NK cell co-culture supernatants by ELISA. (c) Cytotoxicity assay of human NK cells co-cultured with HDCs. HDCs were uninfected, infected with BV at an MOI of 10 or stimulated with LPS (1 μg/ml). Human NK cells purified from PBMCs were then added, together with AsPC-1 target cells, at an E:T ratio of 1:1. After 18 h of incubation, cytotoxic activity against AsPC-1 was analyzed using a cytotoxicity assay kit. measured using ELISA kits (PBL InterferonSource Inc. NJ, USA,
